
    
      This study is a double-blind, randomized controlled trial. 84 patients with type 2 diabetes
      are recruited. After informing the patients about this study and filling the consent letters,
      they are randomly assigned into intervention group (n=42) or placebo group (n=42) receiving
      1500 mg chlorella Vulgaris or placebo daily for 8 weeks. Patients are asked not to change
      their regular physical activity, diet, medicine and dosage during the study. Anthropometric
      and blood pressure measurements are collected and 24-hour food intake recall, IPAQ physical
      activity, Pittsburgh Sleep Quality Assessment (PSQI) and Beck anxiety and depression
      questionnaires are filled by each patients at the beginning and end of the study. In
      addition, blood samples are collected at the beginning and end of the study to determine the
      changes of FBS, HbA1c, insulin concentration and insulin resistance (HOMA-IR) and lipid
      profile.
    
  